News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
NIVEN RALPH
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/07/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/07/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,250 shares
@ $16.256, valued at
$36.6k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 06/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/09/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,045 shares
@ $20.793, valued at
$42.5k
Sold 205 shares
@ $21.6348, valued at
$4.4k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 05/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/08/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,205 shares
@ $23.727, valued at
$52.3k
Sold 45 shares
@ $24.924, valued at
$1.1k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 02/08/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,250 shares
@ $24.272, valued at
$54.6k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
Granted 62,000 options to buy
@ $25.57, valued at
$1.6M
|
|
| 01/09/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,250 shares
@ $26.402, valued at
$59.4k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 12/07/2022 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,250 shares
@ $17.384, valued at
$39.1k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 11/09/2022 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 450 shares
@ $17.091, valued at
$7.7k
Sold 155 shares
@ $18.023, valued at
$2.8k
Sold 1,430 shares
@ $19.823, valued at
$28.3k
Sold 215 shares
@ $20.293, valued at
$4.4k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 10/07/2022 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,059 shares
@ $15.711, valued at
$32.3k
Sold 191 shares
@ $16.218, valued at
$3.1k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 09/07/2022 |
4
| NIVEN RALPH (Chief Scientific Officer) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,250 shares
@ $19, valued at
$42.8k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 08/19/2022 |
4
| NIVEN RALPH (Chief Scientific Officer) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Sold 2,250 shares
@ $21.181, valued at
$47.7k
Exercised 450 options to buy
@ $1.74, valued at
$783
Exercised 200 options to buy
@ $1.74, valued at
$348
Exercised 200 options to buy
@ $2.14, valued at
$428
Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
| 12/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|